# PRESCIENT (pan-cancer early-stage detection, Chinese Academy of Medical Sciences)

Source: https://onco.cc/trials/prescient-cams/  
OnCo record `prescient-cams` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A Chinese study of about 12,000 people testing whether blood proteins and DNA methylation together find several cancers early.

## Summary

PRESCIENT (NCT04822792) is an observational study sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences with Guangzhou Burning Rock Dx Co., Ltd. It aims to detect cancers early with combined serum protein and cell-free DNA methylation assays, with blood RNA markers also evaluated.

The registry record, read on 29 October 2026, gives its status as unknown (the sponsor last updated it on 2 June 2021), with an estimated 11,879 participants, a start on 23 March 2021 and primary completion expected on 31 March 2023.

## Fields

- Kind: Trial
- Last checked: 2026-10-29
- Also known as: PRESCIENT
- Registry id: NCT04822792
- Phase: observational
- Setting: People with cancer, benign disease or no disease in China, testing serum proteins combined with cell-free DNA methylation
- Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences with Guangzhou Burning Rock Dx Co., Ltd.
- Enrolled: 11879

## Sources

- ClinicalTrials.gov NCT04822792: https://clinicaltrials.gov/study/NCT04822792

## Connected records

- fronts: [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)
- companies: [Burning Rock Biotech](https://onco.cc/companies/burning-rock/)

---
JSON: https://onco.cc/api/v1/entities/prescient-cams.json